Skip to main content
PMC home page
Neuroscience Bulletin logoLink to Neuroscience Bulletin
. 2012 Jul 4;28(5):469–474. doi: 10.1007/s12264-012-1256-0

Clinical significance of detection of antibodies to fetal and adult acetylcholine receptors in myasthenia gravis

Qi-Guang Shi 1, Zhi-Hong Wang 1, Xiao-Wei Ma 1, Da-Qi Zhang 1, Chun-Sheng Yang 1, Fu-Dong Shi 1,2, Li Yang 1,✉
PMCID: PMC3600950  NIHMSID: NIHMS448422  PMID: 22961471

Abstract

Objective

To evaluate the frequency, distribution and clinical significance of the antibodies to the fetal and/or adult acetylcholine receptor (AChR) in patients with myasthenia gravis (MG).

Methods

AChR antibodies were detected by cell-based assay in the serum of ocular MG (OMG) (n = 90) and generalized MG (GMG) patients (n = 110). The fetaltype (2α: β: Γ: δ) and adult-type (2α: β: ɛ: δ) AChR were used as antigens, and their relevance to disease presentation was assessed.

Results

The overall frequencies of anti-adult and anti-fetal AChR antibodies were similar in all 200 patients examined, with 14 having serum specific to the AChR-Γ subunit, and 22 to the AChR-ɛ subunit. The overall sensitivity when using the fetal and adult AChR antibodies was higher than that when using the fetal AChR antibody only (P = 0.015). Compared with OMG patients, the mean age at disease onset and the positive ratio of antibodies to both isoforms of the AChR were significantly higher in patients who subsequently progressed to GMG. Older patients and patients with both anti-fetal and anti-adult AChR antibodies had a greater risk for developing generalized disease [odds ratio (OR), 1.03; 95% confidence interval (CI), 1.01–1.06 and OR, 5.09; 95% CI, 2.23–11.62].

Conclusion

Using both fetal- and adult-type AChRs as the antigens may be more sensitive than using either subtype. Patients with serum specific to both isoforms are at a greater risk of progressing to GMG. Patients with disease onset at an advanced age appear to have a higher frequency of GMG conversion.

Keywords: myasthenia gravis, acetylcholine receptor antibodies, acetylcholine receptor subunit, cell-based assay, adult, fetal

Footnotes

These authors contributed equally to this work.

References

  • [1].Vincent A., Palace J., Hilton-Jones D. Myasthenia gravis. Lancet. 2001;357:2122–2128. doi: 10.1016/S0140-6736(00)05186-2. [DOI] [PubMed] [Google Scholar]
  • [2].Yang L., Maxwell S., Leite M.I., Waters P., Clover L., Fan X., et al. Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China. J Neurol Sci. 2011;301:71–76. doi: 10.1016/j.jns.2010.10.023. [DOI] [PubMed] [Google Scholar]
  • [3].Barton J.J., Fouladvand M. Ocular aspects of myasthenia gravis. Semin Neurol. 2000;20:7–20. doi: 10.1055/s-2000-6829. [DOI] [PubMed] [Google Scholar]
  • [4].Kupersmith M.J. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol. 2009;256:1314–1320. doi: 10.1007/s00415-009-5120-8. [DOI] [PubMed] [Google Scholar]
  • [5].Kusner L.L., Puwanant A., Kaminski H.J. Ocular myasthenia: diagnosis, treatment, and pathogenesis. Neurologist. 2006;12:231–239. doi: 10.1097/01.nrl.0000240856.03505.b5. [DOI] [PubMed] [Google Scholar]
  • [6].Grob D. Natural history of myasthenia gravis. In: Engel A.G., editor. Myasthenia Gravis and Myasthenic Disorders. New York, NY: Oxford University Press; 1999. pp. 135–136. [Google Scholar]
  • [7].Luchanok U., Kaminski H.J. Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol. 2008;21:8–15. doi: 10.1097/WCO.0b013e3282f4098e. [DOI] [PubMed] [Google Scholar]
  • [8].Na S.J., So S.H., Lee K.O., Choi Y.C. Elevated serum level of interleukin-32α in the patients with myasthenia gravis. J Neurol. 2011;258:1865–1870. doi: 10.1007/s00415-011-6036-7. [DOI] [PubMed] [Google Scholar]
  • [9].Hong Y.H., Kwon S.B., Kim B.J., Kim B.J., Kim S.H., Kim J.K., et al. Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients. J Neurol Sci. 2008;273:10–14. doi: 10.1016/j.jns.2008.05.023. [DOI] [PubMed] [Google Scholar]
  • [10].MacLennan C., Beeson D., Buijs A.M., Vincent A., Newsom-Davis J. Acetylcholine receptor expression in human extraocular muscles and their susceptibility to myasthenia gravis. Ann Neurol. 1997;41:423–431. doi: 10.1002/ana.410410404. [DOI] [PubMed] [Google Scholar]
  • [11].Ohta K., Fujinami A., Saida T., Nishimura M., Kuno S., Ohta M. Fre quency of anti-AChR epsilon subunit-specific antibodies in MG. Autoimmunity. 2003;36:151–154. doi: 10.1080/0891693031000094935. [DOI] [PubMed] [Google Scholar]
  • [12].Leite M.I., Waters P., Vincent A. Diagnostic use of autoantibodies in myasthenia gravis. Autoimmunity. 2010;43:371–379. doi: 10.3109/08916930903541208. [DOI] [PubMed] [Google Scholar]
  • [13].Allen J.A., Scala S., Jones H.R. Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis. Muscle Nerve. 2010;41:379–384. doi: 10.1002/mus.21555. [DOI] [PubMed] [Google Scholar]
  • [14].Evoli A., Tonali P.A., Padua L., Monaco M.L., Scuderi F., Batocchi A.P., et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126:2304–2311. doi: 10.1093/brain/awg223. [DOI] [PubMed] [Google Scholar]
  • [15].Leite M.I., Jacob S., Viegas S., Cossins J., Clover L., Morgan B.P., et al. IgG1 antibodies to acetylcholine receptors in ’seronegative’ myasthenia gravis. Brain. 2008;131:1940–1952. doi: 10.1093/brain/awn092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [16].Waters P., Jarius S., Littleton E., Leite M.I., Jacob S., Gray B., et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neuro. 2008;65:913–919. doi: 10.1001/archneur.65.7.913. [DOI] [PubMed] [Google Scholar]
  • [17].Kupersmith M.J., Latkany R., Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol. 2003;60:243–248. doi: 10.1001/archneur.60.2.243. [DOI] [PubMed] [Google Scholar]
  • [18].Tzartos S.J., Barkas T., Cung M.T., Mamalaki A., Marraud M., Orlewski P., et al. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev. 1998;163:89–120. doi: 10.1111/j.1600-065X.1998.tb01190.x. [DOI] [PubMed] [Google Scholar]
  • [19].Sheng J.R., Li L.C., Prabhakar B.S., Meriggioli M.N. Acetylcholine receptor-alpha subunit expression in myasthenia gravis: a role for the autoantigen in pathogenesis? Muscle Nerve. 2009;40:279–286. doi: 10.1002/mus.21371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [20].Baggi F., Annoni A., Ubiali F., Milani M., Longhi R., Scaioli W., et al. Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats. J Immunol. 2004;172:2697–2703. doi: 10.4049/jimmunol.172.4.2697. [DOI] [PubMed] [Google Scholar]
  • [21].Lindstrom J.M. Acetylcholine receptors and myasthenia. Muscle Nerve. 2000;23:453–477. doi: 10.1002/(SICI)1097-4598(200004)23:4<453::AID-MUS3>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]
  • [22].Sun C., Meng F., Li Y., Jin Q., Li H., Li F. Antigen-specific immunoadsorption of anti-acetylcholine receptor antibodies from sera of patients with myasthenia gravis. Artif Cells Blood Substit Immobil Biotechnol. 2010;38:99–102. doi: 10.3109/10731191003634778. [DOI] [PubMed] [Google Scholar]
  • [23].Kostelidou K., Trakas N., Tzartos S.J. Extracellular domains of the beta, gamma and epsilon subunits of the human acetylcholine receptor as immunoadsorbents for myasthenic autoantibodies: a combination of immunoadsorbents results in increased efficiency. J Neuroimmunol. 2007;190:44–52. doi: 10.1016/j.jneuroim.2007.07.018. [DOI] [PubMed] [Google Scholar]
  • [24].Kaminski H.J., Kusner L.L., Nash K.V., Ruff R.L. The gamma-subunit of the acetylcholine receptor is not expressed in the levator palpebrae superioris. Neurology. 1995;45:516–518. doi: 10.1212/WNL.45.3.516. [DOI] [PubMed] [Google Scholar]
  • [25].Kaminski H.J., Kusner L.L., Block C.H. Expression of acetylcholine receptor isoforms at extraocular muscle endplates. Invest Ophthalmol Vis Sci. 1996;37:345–351. [PubMed] [Google Scholar]

Articles from Neuroscience Bulletin are provided here courtesy of Springer

RESOURCES